S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion|
|Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014|
|Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes|
|Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014|
|Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014|
|BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology|
|Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes|
|Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab|
|New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time|
|Merck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27|
Click above to view more mutual fund data and stats for 500126 - Merck Ltd.